Undiscovered Info Regarding ATP7A Uncovered By Professionals

In this study, we compared patients receiving GA with patients who switched from GA to other MS therapies in order to assess whether the effectiveness of other MS therapies after the treatment switch was at least comparable to the effectiveness of GA. Materials and Methods This was a retrospective observational study conducted at Hospital Universitario ATP7A Virgen Macarena (Seville, Spain) in accordance with the World Medical Association Declaration of Helsinki, all its amendments and national regulations. All patients provided informed consent for treatment with GA or other MS therapies, which were administered from commercial sources according to the technical specifications and clinical practice. This study was approved by the ethics committee of Hospital Universitario Virgen Macarena (Seville, Spain). Patient population The study population comprised all MS patients included in the database of the Department see more of Neurology at Hospital Universitario Virgen Macarena (Seville, Spain) until October 1st, 2012 who were receiving GA (Copaxone?; Teva Pharmaceuticals Ltd., London, United Kingdom) (GA cohort) and those who switched from GA to other MS therapies due to inadequate effectiveness or adverse events (non-GA cohort). MS was diagnosed according to McDonald criteria (McDonald et?al. 2001) and all treatments were administered according to routine clinical practice. Assessments Study data were obtained through review of information contained in the department's MS patient database, which included demographics, clinical MS characteristics at diagnosis and at the beginning of the study treatments (baseline), and MS course during patients�� follow-up until database lock on October 1st, 2012. The following patients�� data were collected: gender, date of birth, MS diagnosis, clinical findings, evoked potentials, results on magnetic resonance imaging and cerebrospinal fluid analysis, study treatments (drugs and treatment durations), MS duration (at baseline and at the end of the study treatment, if that occurred, or last check-up), EDSS scores (at baseline and at the end of the study treatment, if that occurred, or at last check-up), disability progression until database lock, number of relapses during the Antiinfection Compound Library study treatments, and health-related quality of life (at baseline and at the end of the study treatment, if that occurred, or last check-up). A relapse was defined as the appearance of a new neurologic symptom or worsening of a preexisting one, not attributable to fever or other concurrent phenomenon, which persisted for more than 24?h and became evident during a neurological examination. Quantification of patients�� disability was performed according to EDSS scores (Kurtzke 1983). Disability progression was defined as an increase in EDSS scores ��1.0 points for patients with EDSS scores